Mon, Feb 24, 7:31 AM, Zacks Surging Earnings Estimates Signal Good News for Pharmacyclics (PCYC) - Tale of the Tape Pharmacyclics has decent short-term momentum and solid activity on the earnings estimate revision front. These positive earnings estimate revisions suggest that analysts are becoming more optimistic on PCYC’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Pharmacyclics could be a solid choice for investors.
Pharmacyclics is a biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. Co. has three proprietary drug candidates under clinical development and several preclinical lead molecules: an inhibitor of Bruton's tyrosine kinase (BTK) ibrutinib in several Phase III studies in hematologic malignancies, a BTK inhibitor lead optimization program targeting anti-inflammatory and autoimmune indications, an inhibitor of Factor VIIa in a Phase II clinical trial in pancreatic cancer and a histone deacetylase inhibitor, abexinostat, in Phase I and II clinical trials in solid tumors and hematological malignancies.
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Service. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20
minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.